Citations

Clear

6274 citation(s) found for "To, Andrew".

Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis
Sechi, Elia , Krecke, Karl N. , Pittock, Sean J. , Ferrari, Sérgio , Monaco, Salvatore , Zanzoni, Serena , Rabinstein, Alejandro A. , Wingerchuk, Dean M. , Nasr, Deena M. , Zalewski, Nicholas L. , Pittock, S J , Sechi, Elia , Rabinstein, Alejandro A , Ferrari, Sergio , Mariotto, Sara , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Stroke | January 11, 2021 | Volume: 52 | Issue: 2 | Pages: 645-654

10.1161/strokeaha.120.031482 | PMID 33423516 Get It

Background and Purpose: The diagnosis of spontaneous spinal cord infarction (SCI) is limited by the lack of diagnostic biomarkers and MRI features that often overlap with those of other myelopathies, especially acute myelitis. We investigated whether the ratio between serum neurofilament light chain levels and MRI T2-lesion area (neurofilament light chain/area ratio—NAR) differentiates SCI from acute myelitis of similar severity. Methods: We retrospectively identified Mayo Clinic patients (January 1, 2000–December 31, 2019) with (1) SCI, (2) AQP4 (aquaporin 4)-IgG or MOG (myelin oligodendrocyte glycoprotein)-IgG-associated myelitis at disease clinical presentation, or (3) idiopathic transverse myelitis from a previously identified population-based cohort of patients seronegative for AQP4-IgG and MOG-IgG. Serum neurofilament light chain levels (pg/mL) were assessed at the Verona University (SIMOA, Quanterix) in a blinded fashion on available stored samples obtained ≤3 months from myelopathy presentation. For each patient, the largest spinal cord lesion area (mm 2 ) was manually outlined by 2 independent raters on sagittal T2-weighted MRI images, and the mean value was used to determine NAR (pg/[mL·mm 2 ]). Results: Forty-eight patients were included SCI, 20 (definite, 11; probable, 6; possible, 3); acute myelitis, 28 (AQP4-IgG-associated, 17; MOG-IgG-associated, 5; idiopathic transverse myelitis, 6). The median expanded disability status scale score (range) at myelopathy nadir were 7.75 (2–8.5) and 5.5 (2–8), respectively. Serum neurofilament light chain levels (median [range] pg/mL) in patients with SCI (188 [14.3–2793.4]) were significantly higher compared with patients with AQP4-IgG-associated myelitis (37 [0.8–6942.9]), MOG-IgG-associated myelitis (45.8 [4–283.8]), and idiopathic transverse myelitis (15.6 [0.9–217.8]); P =0.01. NAR showed the highest accuracy for identification of SCI versus acute myelitis with values ≥0.35 pg/(mL·mm 2 ) yielding 86% specificity and 95% sensitivity (area under the curve=0.93). The positive and negative likelihood ratios were 6.67 and 0.06, respectively. NAR remained independently associated with SCI after adjusting for age, gender, immunotherapy before sampling, and days from myelopathy symptoms onset to sampling ( P =0.0007). Conclusions: NAR is a novel and promising clinical biomarker for differentiation of SCI from acute myelitis.
Roundtable on Preseason Heat Safety in Secondary School Athletics: Environmental Monitoring During Activities in the Heat
Hosokawa, Yuri , Adams, William M. , Vanos, Jennifer , Cooper, Earl R. , Grundstein, Andrew , Jay, Ollie , Otani, Hidenori , Stearns, Rebecca L. , Tripp, Brady L. , Raukar, Neha P. , Adams, William M , Casa, Douglas J. , McDermott, Brendon P.

Mayo Clinic

Journal of Athletic Training | January 10, 2021 | Volume: 56 | Issue: 4 | Pages: 362-371

10.4085/1062-6050-0067.20 | PMID 33400785 Get It

Objective To develop best-practice recommendations using thermal indices to determine work-to-rest ratios and facilitate further implementation of environmental monitoring for heat safety in secondary school athletics in the United States. Data Sources A narrative review of the current literature on environmental monitoring for heat safety during athletics was conducted by content experts. A list of action-oriented recommendations was established from the narrative review and further refined using the Delphi method. Conclusions Assessment of wet bulb globe temperature at the site of activity and throughout the duration of the event is recommended to assist clinicians and administrators in making appropriate decisions regarding the duration and frequency of activity and rest periods. Activity-modification guidelines should be predetermined and approved by stakeholders and should outline specific actions to be followed, such as the work-to-rest ratio, frequency and timing of hydration breaks, and adjustment of total exercise duration, equipment, and clothing. Furthermore, integration of exertional heat illness injury data with environmental condition characteristics is critical for the development of evidence-based heat safety guidelines for secondary school athletics. Athletic trainers play an essential role in conducting prospective injury data collection, recording onsite wet bulb globe temperature levels, and implementing recommendations to protect the health and safety of athletes.
Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility
Kashour, Tarek , Sohail, M. Rizwan , O’Horo, John C. , Badley, Andrew D. , Tleyjeh, Imad M. , O'Horo, John C, Tleyjeh, Imad M , Sohail, M Rizwan , Badley, Andrew D , O'Horo, John C , Halwani, Rabih , Arabi, Yaseen M.

Mayo Clinic

Immunopharmacology and Immunotoxicology | January 7, 2021 | Volume: 43 | Issue: 1 | Pages: 37-50

10.1080/08923973.2020.1863984 | PMID 33406943 Get It

Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis
Valencia-Sánchez, Cristina , Pittock, Sean J. , Mead‐Harvey, Carolyn , Dubey, Divyanshu , López‐Chiriboga, A. Sebastian , Trenerry, Max R., Zalewski, Nicholas L. , Ζεκερίδου, Αναστασία , Lopez-Chiriboga, Sebastian, Pittock, S J , Dubey, Divyanshu , Valencia Sanchez, Cristina , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Brain Communications | January 6, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa233 | PMID 34061124 Get It

Abstract Hashimoto encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis, has been defined by sub-acute onset encephalopathy, with elevated thyroid antibodies, and immunotherapy responsiveness, in the absence of specific neural autoantibodies. We aimed to retrospectively review 144 cases referred with suspected Hashimoto encephalopathy over a 13-year period, and to determine the clinical utility of thyroid antibodies in the course of evaluation of those patients. One hundred and forty-four patients (all thyroid antibody positive) were included; 72% were women. Median age of symptom onset was 44.5 years (range, 10–87). After evaluation of Mayo Clinic, 39 patients (27%) were diagnosed with an autoimmune CNS disorder [autoimmune encephalopathy (36), dementia (2) or epilepsy (1)]. Three of those 39 patients had neural-IgGs detected (high glutamic acid decarboxylase-65, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-receptor and neural-restricted unclassified antibody), and 36 were seronegative. Diagnoses among the remaining 105 patients (73%) were functional neurological disorder (n = 20), neurodegenerative disorder (n = 18), subjective cognitive complaints (n = 14), chronic pain syndrome (n = 12), primary psychiatric (n = 11), sleep disorder (n = 10), genetic/developmental (n = 8), non-autoimmune seizure disorders (n = 2) and other (n = 10). More patients with autoimmune CNS disorders presented with sub-acute symptom onset (P < 0.001), seizures (P = 0.008), stroke-like episodes (P = 0.007), aphasia (P = 0.04) and ataxia (P = 0.02), and had a prior autoimmune history (P = 0.04). Abnormal brain MRI (P = 0.003), abnormal EEG (P = 0.007) and CSF inflammatory findings (P = 0.002) were also more frequent in the autoimmune CNS patients. Patients with an alternative diagnosis had more depressive symptoms (P = 0.008), anxiety (P = 0.003) and chronic pain (P = 0.002). Thyoperoxidase antibody titre was not different between the groups (median, 312.7 versus 259.4 IU/ml; P = 0.44; normal range, <9 IU/ml). None of the non-autoimmune group and all but three of the CNS autoimmune group (two with insidious dementia presentation, one with seizures only) fulfilled the autoimmune encephalopathy criteria proposed by Graus et al. (A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391–404.) (sensitivity, 92%; specificity, 100%). Among patients who received an immunotherapy trial at our institution and had objective post-treatment evaluations, the 16 responders with autoimmune CNS disorders more frequently had inflammatory CSF, compared to 12 non-responders, all eventually given an alternative diagnosis (P = 0.02). In total, 73% of the patients referred with suspected Hashimoto encephalopathy had an alternative non-immune-mediated diagnosis, and more than half had no evidence of a primary neurological disorder. Thyroid antibody prevalence is high in the general population, and does not support a diagnosis of autoimmune encephalopathy in the absence of objective neurological and CNS-specific immunological abnormalities. Thyroid antibody testing is of little value in the contemporary evaluation and diagnosis of autoimmune encephalopathies.
Visualization of user interactions with a pressure mapping mobile application for wheelchair users at risk for pressure injuries
Goodwin, Brianna M. , Olney, Christine M. , Ferguson, John E. , Hansen, Andrew H. , Eddy, Byron , Goldish, Gary D, Morrow, Melissa M. , Vos-Draper, Tamara , Vos-Draper, Tamara L , Morrow, Melissa M

Mayo Clinic

Assistive Technology | January 4, 2021 | Volume: 34 | Issue: 4 | Pages: 444-453

10.1080/10400435.2020.1862938 | PMID 33395558 Get It

681. Induction Immunosuppression Selection in People Living with HIV Undergoing Deceased Donor Kidney Transplantation: U.S. National Trends from 2000 to 2018
Vijayvargiya, Prakhar , Gurram, Pooja , Rizza, Stacey A. , Dean, Patrick G. , Cevallos, Edison Cano , Mullan, Aidan F. , Shweta, Fnu , Mahmood, Maryam , Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Open Forum Infectious Diseases | January 2, 2021 | Volume: 7 | Issue: Supplement_1 | Pages: S394-S394

10.1093/ofid/ofaa439.873 Get It

Abstract Background Human Immunodeficiency Virus (HIV) outcomes have significantly improved at the expense of other age-related diseases including chronic kidney disease. Early reports of people living with HIV (PLWH) undergoing deceased-donor kidney transplantation (DDKT) showed poor outcomes, but these have notably improved after introduction of antiretrovirals. Despite years of experience, the optimal induction immunosuppression (IIS) in PLWH remains subject of debate. Large-scale studies describing the current ISS practices in PLWH undergoing DDKT are lacking. Here, we describe the U.S. national trends of IIS used in PLWH undergoing DDKT from 2000 to 2018 using the United Network of Organ Sharing (UNOS) database. Methods We analyzed the UNOS database to determine the selection of IIS in PLWH undergoing first-time DDKT between 1/1/2000 and 12/31/2018. Cases with unknown HIV status at the time of transplant were excluded. Age, sex and demographics were analyzed. The regimen used for IIS was compared based on HIV serostatus and the change in induction regimen was trended over time. Results A total of 139,650 cases underwent DDKT during the study period. Among these, 1,384 were identified as HIV-positive. PLWH were significantly younger than HIV-negative (49±10 years vs. 51.6 ± 15.3 years; p< 0.001) (Table 1). A greater proportion of men was seen in the PLWH group compared to HIV-negative persons (76.2% vs. 60.4%; p< 0.0001). In the HIV-negative group, 12.1% undergoing DDKT did not receive IIS compared to 16.4% in PLWH (p< 0.0001). Medications that have significantly increased in use with years in PLWH included rabbit anti-thymocyte globulin (rATG), steroids, and basiliximab (3.54, 3.25, 2.28, respectively; p< 0.001). On our trend analysis (Figure 1), the percentage of PLWH receiving any IIS is increasing by 4.04% each year (p< 0.001). Table 1 Figure 1 Conclusion Our study suggests that IIS is an increasing practice in PLWH undergoing DDKT, predominantly using rATG, steroids, and basiliximab. Understanding the current practices might lead to further studies to determine the long-term outcomes after different induction regimens in PLWH. Disclosures All Authors: No reported disclosures
1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
Sigler, Carly, Frens, Jeremy J , Howard, Catessa, Barger, Melissa, Lagnf, Abdalhamid M, Alosaimy, Sara , Rybak, Michael J. , Morrisette, Taylor , Philley, Julie V. , Webb, Andrew , Stevens, Ryan W. , Bouchard, Jeannette L. , Bookstaver, P. Brandon

Mayo Clinic

Open Forum Infectious Diseases | January 2, 2021 | Volume: 7 | Issue: Supplement_1 | Pages: S660-S660

10.1093/ofid/ofaa439.1473 Get It

Abstract Background Omadacycline (OMC) is an aminomethylcycline antibiotic in the tetracycline class that has been Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. OMC has been shown to have potent in vitro activity against a broad-spectrum of Gram-positive and Gram-negative organisms, as well as Nontuberculous Mycobacteria (NTM). Due to it’s unique activity and availability as an oral agent, off-label use of OMC has been increasing. We evaluated the real-world effectiveness and safety of OMC for a variety of infections. Methods This was a multicenter, retrospective, observational study that was conducted from January 2020 to June 2020. We included all patients ≥ 18 years of age that received OMC for ≥ 72 hours for any indication and/or pathogen. The primary outcome was clinical success, defined as a lack of 30-day (non-NTM) or 90-day (NTM) mortality or microbiologic recurrence and absence of therapy escalation or alteration. Reasons for OMC utilization and incidence of potential adverse effects attributable to OMC were also analyzed. Results A total of 18 patients were included from six geographically distinct academic health systems (median age: 56 (IQR, 49-60.5) years; 61% male; 72% Caucasian). The majority of OMC use was in NTM (61%; 100% Mycobacterium abscessus) and in Acinetobacter baumannii (22%) for bone/joint (39%) and respiratory tract (33%) infections. OMC was used primarily in the outpatient setting alone (83%) and most isolates did not have OMC susceptibility conducted (89%). Clinical success was reported in 83% of the total population (71% non-NTM and 91% NTM). The majority of patients were prescribed OMC due to antimicrobial resistance to previous antibiotic(s) (61%) and/or due to OMC’s availability as an oral agent (44%). Three patients experienced side effects while on therapy (serum creatinine elevation, AST/ALT increase, and gastrointestinal distress). Conclusion OMC appears to be effective and well-tolerated for a variety of infections caused by various pathogens, including M. abscessus and A. baumannii. Disclosures Michael J. Rybak, PharmD, MPH, PhD, Paratek (Grant/Research Support)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses
Pilotto, Andrea , Masciocchi, Stefano , Volonghi, Irene , Giuli, Valeria De , Caprioli, Francesca, Bozzetti, Silvia , Imarisio, Alberto , Risi, Barbara , Benussi, Alberto , Castelli, Francesco , Stefanelli, Paola , Ζεκερίδου, Αναστασία , Ashton, Nicholas J. , Blennow, Kaj , Padovani, Alessandro , Padovani, Alessandro , Ashton, Nicholas J , Mariotto, Sara , Ferrari, Sérgio , Premi, Enrico , Focà, Emanuele , Zanusso, Gianluigi , Monaco, Salvatore , Gasparotti, Roberto , McKeon, Andrew , Zetterberg, Henrik

Mayo Clinic

Clinical Infectious Diseases | January 1, 2021 | Volume: 73 | Issue: 9 | Pages: e3019-e3026

10.1093/cid/ciaa1933 | PMID 33395482 Get It

Abstract Background Recent findings indicated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related neurological manifestations involve cytokine release syndrome along with endothelial activation, blood brain barrier dysfunction, and immune-mediated mechanisms. Very few studies have fully investigated the cerebrospinal fluid (CSF) correlates of SARS-CoV-2 encephalitis. Methods Patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection and encephalitis (COV-Enc), encephalitis without SARS-CoV-2 infection (ENC), and healthy controls (HC) underwent an extended panel of CSF neuronal (neurofilament light chain [NfL], T-tau), glial (glial fibrillary acidic protein [GFAP], soluble triggering receptor expressed on myeloid cells 2 [sTREM2], chitinase-3-like protein 1 [YKL-40]) and inflammatory biomarkers (interleukin [IL]-1β, IL-6, Il-8, tumor necrosis factor [TNF] α, CXCL-13, and β2-microglobulin). Results Thirteen COV-Enc, 21 ENC, and 18 HC entered the study. In COV-Enc cases, CSF was negative for SARS-CoV-2 real-time PCR but exhibited increased IL-8 levels independently from presence of pleocytosis/hyperproteinorracchia. COV-Enc patients showed increased IL-6, TNF- α, and β2-microglobulin and glial markers (GFAP, sTREM2, YKL-40) levels similar to ENC but normal CXCL13 levels. Neuronal markers NfL and T-tau were abnormal only in severe cases. Conclusions SARS-CoV-2-related encephalitis were associated with prominent glial activation and neuroinflammatory markers, whereas neuronal markers were increased in severe cases only. The pattern of CSF alterations suggested a cytokine-release syndrome as the main inflammatory mechanism of SARS-CoV-2-related encephalitis.
Is It Time to Move On? Reexamining Race in Glomerular Filtration Rate Equations
Moderators:, Ovalle, Anais , Cervinski, Mark A , Experts:, Levey, Andrew S. , Jones, Graham , Eneanya, Nwamaka D. , Jha, Vivekanand , Cervinski, Mark A , Moderators:, El-Khoury, Joe M , Experts:, Lieske, John C.

Mayo Clinic

Clinical Chemistry | December 30, 2020 | Volume: 67 | Issue: 4 | Pages: 585-591

10.1093/clinchem/hvaa333 | PMID 33686430 Get It

Recent Trends in Youth Concussions: A Brief Report
Askow, Andrew T. , Erickson, Jacob L. , Jagim, Andrew R , Askow, Andrew T , Jagim, Andrew R.

Mayo Clinic

Journal of Primary Care & Community Health | December 29, 2020 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2150132720985058 | PMID 33372578 Get It

Objectives Concussions and mild traumatic brain injuries are important medical issues, particularly among youth as the long-term health consequences of these injuries can become increasingly problematic. The purpose of this study was to examine recent trends in diagnosed concussions among pediatric patients in a large health care system. Methods This was a retrospective, population-based epidemiology study design that queried all patient files (pediatrics included) using electronic medical health records and further stratified patients based on type of concussion, age, sex, and year from 2013 to 2018. Results Electronic health records from a cohort of 8 832 419 (n males = 4 246 492; n females = 4 585 931) patient visits were assessed for concussion diagnosis and filtered for those whose concussive event led to a loss of consciousness (LOC) or not (nLOC). Of these patients, 12 068 were diagnosed with a concussion (LOC = 3 699; nLOC = 8 369) with an overall incidence rate of 1.37 concussions per 1000 patients. Overall, the number of patients diagnosed with a concussion increased by 5063 (LOC = 1351; nLOC = 3712) from 2013 to 2018. Males and females presented with similar rates of concussions 5919 (49.05%) and 6149 concussions (50.95%), respectively. Of total diagnosed concussions, 4972 (LOC = 815; nLOC = 4157) were under the age of 18 and represented 41.2% of all diagnosed concussions with an incidence rate of 6.79 per 1000 patients. Conclusion The number of concussions diagnosed appear to be on the rise with the largest number of concussions being diagnosed in those under the age of 18. Future studies should seek to determine primary causality and the long-term health implications of concussions with or without LOC.